CNSY$1.28-25.44%
Cerenome, Inc.
Sector: Surgical & Medical Instruments & ApparatusIndustry: Medical - PharmaceuticalsCountry: USExchange: Nasdaq
Mkt Cap:$9.68M
Float & O/S:
Inst Own:
DilutionScan read 24 of CERENOME, INC.'s SEC filings and found 5 warrant series, 7 convertibles, 2 ATM programs, 2 equity lines, 3 shelf registrations, 4 S-1 registrations and 3 completed offerings on file for CNSY. The latest dilution event on file is an offering on Sep 10, 2026. Analysis updated Oct 6, 2026.
Signal8 Summary
1h old
CNSY
Cash crunch despite pipeline progress
- Business
- WeakNet loss $22.4M on $5.2M revenue, runway ~1 month
- Stock risk
- High$9.6M micro-cap, 1-for-25 reverse split, shares +910% YoY
Snapshot
Cerenome is a clinical-stage cancer company with a small but growing diagnostics business. FY 2025 revenue was $5.2M, down 10.5% YoY, while the net loss was $22.4M, more than four times revenue.
What's Happening Right Now
- : Cerenome completed enrollment in its Phase 2 ReSPECT-GBM trial of REYOBIQ in recurrent glioblastoma on Oct 29, 2026, with topline data expected mid-2027.
- : Cerenome will present interim safety and biomarker data from the first 10 patients in its ReSPECT-LMM study at the SNO Annual Meeting, Nov 12-15, 2026.
- : Cerenome's CNSide Diagnostics signed an in-network agreement with Florida Blue effective Oct 1, 2026, bringing total contracted payer coverage to approximately 164 million lives.
- : Cerenome's CNSide Diagnostics commercially launched two new CSF-based molecular profiling tests in the U.S. starting Oct 12, 2026, expanding beyond its original leptomeningeal metastases test.
- : On Sep 10, 2026, Cerenome entered a senior secured financing facility of up to $20 million with 3i, LP, structured with royalty-based repayments to fund CNSide commercial scale-up.
- : Raised $3.00M in gross proceeds through a private placement (PIPE), and a $3.19M convertible note.
- : Sold $1.80M net / 436K shares through its at-the-market program, as stated for Apr 1, 2026 to Jun 30, 2026.
- : Sold $1.80M net / 436K shares through its at-the-market program, as stated for Jan 1, 2026 to Jun 30, 2026.
